Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Questionnaire Administration

Related Conditions

Often studied with 17 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02333188Phase 1Completed

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

NCT02356471Not ApplicableCompletedPrimary

Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery

Showing all 2 trials

Research Network

Common Treatments

  • Questionnaire Administration1
  • Fluorouracil1
  • Laboratory Biomarker Analysis1
  • Management Of Therapy Complications Fitbit Zip Portable Pedometer Device1
  • Paclitaxel Albuminstabilized Nanoparticle Formulation1

Active Sponsors

  • National Cancer Institute (NCI)2
  • Wake Forest University Health Sciences1
  • University of Chicago1

Top Investigators

Related Conditions

  • Stage Iiia Gallbladder Cancer1
  • Stage Iv Gallbladder Cancer1
  • Stage Iii Pancreatic Cancer1
  • Gallbladder Carcinoma1
  • Adenocarcinoma Of Unknown Primary1

Activity Timeline